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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not droxidopa
is safe and effective in reducing the symptoms of neurogenic orthostatic hypotension.
Study Design: Systemic review of three English-language primary studies, conducted in 2014 or
later.
Data Sources: Three double-blind, randomized trials comparing the safety and efficacy of
droxidopa to placebo in patients with diagnosed neurogenic orthostatic hypotension, found via
PubMed in peer-reviewed journals.
Outcomes Measured: Improvement of symptoms was measured utilizing patient responses to
the Orthostatic Hypotension Questionnaire (OHQ), which consists of a six item Orthostatic
Hypotension Symptom Assessment (OSHA) and the four item Orthostatic Hypotension Daily
Activity Scale (OHDAS), each measured on a 1-10 scale. Also utilized was the patient-rated
Clinical Global Impression (CGI) severity and improvement 7-point scales. Safety was
measured through incidence of adverse effects during the randomized trial.
Results: Biaggioni, et al, exhibited 46% of droxidopa recipients describing themselves as much
or very much improved according to CGI ratings, compared to 27.5% of those receiving placebo,
although with a p-score of 0.384. Hauser, et al, exhibited mean improvement in OSHA item 1 at
week 1 as 2.3 for droxidopa, compared to 1.3 in the control group, with a p-value of 0.018.
Kaufmann, et al, exhibited improvement of greater than 3 units in composite OHQ score in
27.2% of droxidopa recipients compared to 11.4% of placebo recipients, with a p score of 0.016.
Numbers needed to harm were presented for each studied, obtained through measurement of
adverse effects of experiment vs control during randomized trial, and consisted of -13 in
Biaggioni, et al, 38 in Hauser, et al, and 28 in Kaufmann, et al.
Conclusions: These results indicate that droxidopa showed statistical improvement in symptoms
in two studies and numerical improvement in another, in addition to being relatively well
tolerated. However, the difference in end points measured in each studies and inconsistencies in
study design prevent any strong conclusion, and further study is required.
Key Words: droxidopa, neurogenic orthostatic hypotension
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Introduction
Neurogenic orthostatic hypotension (nOH) is a reduction in sustained blood pressure as a
result of inadequate norepinephrine response to postural changes. This paper evaluates three
randomized, double-blind, placebo-controlled trials comparing the efficacy of droxidopa in
treatment of neurogenic orthostatic hypotension compared to placebo.
Neurogenic orthostatic hypotension is a common complication for patients with
Parkinson’s disease, with its prevalence ranging from 16 to 58%.1 It is also seen in 30 to 50% of
patients with dementia with Lewy bodies.1 NOH is also considered a hallmark sign of Multiple
System Atrophy (MSA), affecting about 80% of patients with that diagnosis.2 The presence of
orthostatic hypotension has also been shown to increase the 4 year age-adjusted mortality rate
compared to patients without the diagnosis.3
Neurogenic orthostatic hypotension can also present significant costs to the health care
system, largely due to its effect of increasing the risk of falls in patients who are affected. The
use of droxidopa resulted in estimated cost savings of $14,574 over 12 months, and was also
cost-effective against the standard of care.5 Proper treatment of neurogenic orthostatic
hypotension could also help to prevent the burden on the health care system by reducing health
care visits for the condition. Although the specific numbers are unavailable for neurogenic
orthostatic hypotension, the prevalence of general orthostatic hypotension in the elderly is
estimated to be between 5 and 30%.3
Orthostatic hypotension is typically defined as a blood pressure drop of 20 mm Hg in
systolic blood pressure or a drop of 10 mm Hg in diastolic blood pressure within 3 minutes of
standing.1 When this drop is attributed to a deficit within the autonomic nervous system reflexes,
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where the body does not release enough norepinephrine to counteract postural changes, it is
termed neurogenic orthostatic hypotension (nOH).5 This deficit can result in a variety of
symptoms, such as dizziness and syncope, that can contribute significantly to the morbidity and
mortality of patients afflicted by it.1 However, the true prevalence and morbidity associated with
neurogenic orthostatic hypotension is unknown, due to its potential to exist asymptomatically for
long periods of time and the multifactorial conditions of many falls.
There are currently limited options available for treatment of nOH. Non-pharmacologic
treatment, composed mostly of a stepwise progression when changing position to standing and
increased physical conditioning, is often recommended.1 The only other FDA-approved
medication for nOH is midodrine, an oral prodrug that is converted into desglymidrodrine, a
selective α1-adrenoceptor agonist.6 Although midodrine is generally well-tolerated, its use can
be limited by adverse effects and there are some questions regarding its efficacy in treating this
condition.6 As such, droxidopa is a potential option as a more efficacious and cost-effective
treatment for neurogenic orthostatic hypotension.
Objective
The objective of this selective EBM review is to determine whether or not droxidopa is
safe and effective in reducing the symptoms of neurogenic orthostatic hypotension.
Methods
Specific criteria were used during the selection of studies for use in this review. The
population was composed of men and women over the age of 18 with the diagnosis of
neurogenic orthostatic hypotension. In all three studies, the intervention utilized was droxidopa
(L-threo-3,4-dihydroxyphenylserine) which was dose optimized for each patient. Each consisted
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of a treatment group receiving droxidopa, which was compared to a control group receiving
placebo. Two studies measured outcomes according to improvement in the symptoms of
neurogenic orthostatic hypotension as determined by the patient-rated Orthostatic Hypotension
Questionnaire (OHQ). The third was also measured according to improvement in the symptoms
of nOH, but determined by the self-rated Clinical Global Impression (CGI) severity and
improvement scales. All studies included are randomized, double-blind, placebo controlled
trials.
Research was conducted utilizing the key words of “droxidopa” and “neurogenic
orthostatic hypotension”. All articles were published in English with peer-reviewed journals,
and were selected according to their relevance to the objective of the paper and their use of
patient-oriented outcomes (POEMS). Inclusion criteria consisted of studies utilizing patients
over the age of 18 and conducted utilizing a randomized, placebo-controlled format. Exclusion
criteria included patients under the age of 18 and studies which exclusively measured diseaseoriented evidence (DOEs) such as blood pressure readings. The statistics used and reported
include p-values, numbers needed to treat (NNT), numbers needed to harm (NNH), relative
benefit increase (RBI), relative risk increase (RRI), absolute benefit increase (ABI), and absolute
risk increase (ARI).
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Table 1: Demographics and Characteristics of Included Studies
Study

Type

# Pts

Age
(yrs)
2488

Inclusion
Criteria
Patients over 18
years old with a
clinical diagnosis
of symptomatic
OH, and met
responder
criteria

Biaggioni6
(2015)

RCT

101

Hauser7 (2015)

RCT

174

4191

Patients over 18
years old with a
clinical diagnosis
of Parkinson’s
disease and signs
and symptoms of
nOH

Kaufmann8
(2014)

RCT

168

1887

Patients over 18
years old with a
clinical diagnosis
of nOH and met
responder
criteria

Exclusion Criteria
Pre-existing sustained
severe hypertension,
atrial fibrillation or
significant cardiac
arrhythmia, current
use of tricyclic
antidepressants or
other norepinephrine
reuptake inhibitors,
current use of
antihypertensive
medication or use of
vasoconstrictive
agents within 2 days
before baseline
Use of
vasoconstricting
agents or long-acting
antihypertensive
medications;
sustained, severe
hypertension, a MiniMental State
Examination score
under 23, significant
uncontrolled cardiac
arrhythmia, unstable
angina, congestive
heart failure, or a
history of myocardial
infarction
Use of vasoconstrictor
agents within 2 days
before baseline, use of
long-acting
antihypertensives or
norepinephrine
reuptake inhibitors,
sustained, severe
supine hypertension,
and significant
systemic, hepatic,
cardiac or renal
disease

W/
D
14

Intervention

45

8 weeks of
maintenance at
optimized dosage
of droxidopa
(100-600mg TID)

9

Droxidopa
initiated at 100mg
TID and titrated in
100mg increments
until optimized

Dose optimized
droxidopa,
initiated at 100
mg capsules 3x
daily and adjusted
upwards at 100
mg 3x daily
increments until
optimal dose
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Outcomes Measured
In each of the three RCTs utilized, the outcomes were measured according to
improvement of the symptoms of neurogenic orthostatic hypotension. In one study, the primary
outcomes assessed were symptoms according to the Clinical Global Impression (CGI) severity
and improvement scales, which were self-rated by patients. CGI severity is a 7 point scale
scored from 1 (no symptoms) to 7 (severe symptoms) and improvement is a 7 point scale scored
from 1 (very much improved) to 7 (very much worse).
In the other two studies, the primary outcomes assessed were symptoms according to the
Orthostatic Hypotension Questionnaire (OHQ), which consists of a six item Orthostatic
Hypotension Symptom Assessment (OSHA) and the four item Orthostatic Hypotension Daily
Activity Scale (OHDAS), with each self-rated by patients on a 1-10 scale. The items of OSHA
were dizziness/lightheadedness, vision disturbance, weakness, fatigue, trouble concentrating, and
head and neck discomfort. The items of OHDAS were interference with standing for a short
time, standing for a long time, walking for a short time, and walking for a long time.
Results
Three randomized placebo-controlled trials evaluated the effect of droxidopa on the
symptoms of neurogenic orthostatic hypotension. All studies were conducted on patients aged
18 years or older, in addition to other inclusion criteria as outlined in Table 1. All patients under
age 18 were excluded, in addition to the variety of exclusion criteria provided in Table 1, which
helped to isolate adverse effects to the trial drug in question instead of comorbid conditions.
The study conducted by Biaggioni, et al was conducted on 101 randomized patients,
which excluded 43 patients who discontinued due to adverse effects and 24 who did not meet
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responder criteria at the maximum dosage of droxidopa.6 In this withdrawal study, patients were
continued on their optimized droxidopa, at 100-600mg TID, for 1 week before being
randomized, and either continued on droxidopa or withdrawn to placebo for 14 days.6
Symptoms were then evaluated utilizing the OHQ and CGI patient scale, with the primary end
point item 1 of the OSHA and the remainder of the data functioning as secondary end points.
From randomization to end of study, item 1 increased by 1.3 units on average for the
droxidopa treatment group, compared to 1.9 units on average for the placebo group, with a pvalue of 0.509.6 All other units of the OSHA questionnaire and the composite score similarly
failed to reach statistical significance, although all but item 2 favored droxidopa numerically.
When evaluating through CGI scores, 46% of patients on droxidopa rated themselves as much or
very much improved, compared to 27.5% of the placebo group.6 This led to a relative benefit
increase of 67%, an absolute benefit increase of 18.5%, and a numbers needed to treat of 6 for
this particular endpoint. This data is also exhibited in Table 2. However, the improvement
scores according to CGI for patient’s self ratings only had a p score of 0.384.6
The second study, conducted by Hauser, et al, utilized 8 weeks of treatment maintenance
at the optimized dose of droxidopa, ranging between 100-600mg TID.7 Non-responders were
not removed from the study prior to randomization, unlike the other two studies included in this
analysis. Patient reported scores for item 1 of the OSHA score were then measured as the
primary endpoint, with data taken at weeks 1, 2, 4 and 8 and compared to baseline.7 Mean
improvement at week 1 was 2.3, with a standard deviation of 2.95, compared to 1.3 with
standard deviation of 3.16 in the control group, with a p-value of 0.018.7 Improvement in weeks
2, 4 and 8 also favored droxidopa, but not to a statistically significant degree.
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In the final study, conducted by Kaufmann, et al, 263 patients participated in open label
droxidopa optimization, with 162 responders subsequently randomized into double blind placebo
or droxidopa.8 Following a 1 week washout period, patients were either continued at their
optimized dosage of droxidopa, 100-600mg TID, or provided placebo.8 The primary endpoint
was determined as improvement from baseline in mean composite OHQ score, with specific
attention paid to improvement of greater than 3 points from baseline.
Droxidopa patients had a mean change of -1.83 units in OHQ score, compared to a -0.90
in the placebo group, favoring droxidopa with a p score of 0.003.8 In addition, improvement was
greater than 3 units in 27.2% of droxidopa recipients compared to 11.4% of placebo recipients,
with a p score of 0.016.8 This particular endpoint results in a relative benefit increase of 139%,
an absolute benefit increase of 15.8%, and a numbers needed to treat of 7 for droxidopa. This
data is also exhibited in Table 2.
Table 2: Efficacy of Treatment, Experiment vs Control
Study

Control event
rate (CER)

Experimental
event rate
(EER)

Biaggioni6
Kaufmann8

27.5%
11.4%

46%
27.2%

Relative
benefit
increase
(RBI)
67%
139%

Absolute
benefit
increase
(ABI)
18.5%
15.8%

Numbers
needed to
treat (NNT)
6
7

In all three studies, droxidopa was generally well-tolerated, as evidence by the data
provided in table 3. During double blind treatment in the study conducted by Biaggioni, et al,
30% of droxidopa recipients reported at least one adverse effect, compared to 37.3% of those
who received placebo treatment.6 In the study conducted by Hauser, et al, 82% of droxidopa
recipients reported adverse effects during treatment, compared to 79.3% of the placebo group.7
And during double blind treatment in the study conducted by Kaufmann, et al, 18.5% of
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droxidopa recipients reported adverse effects to treatment compared to 14.8% of placebo
recipients.8 A complete collection of this data, including relative risk increase, absolute risk
increase, and the numbers needed to harm (NNH) are provided in Table 3.
Table 3: Adverse Effects of Treatment, Experimental vs Placebo
Study
Biaggioni6
Hauser7
Kaufmann8

Control
event rate
(CER)
37.3%
79.3%
14.8%

Experimental
event rate (EER)
30%
82%
18.5%

Relative risk
increase
(RRI)
-20%
3.4%
25%

Absolute risk
increase
(ARI)
-7.3%
2.7%
3.7%

Numbers
needed to
harm (NNH)
-13
38
28

Discussion
This systemic review analyzed 3 randomized, placebo-controlled trials to evaluate the
efficacy and safety of droxidopa as a treatment for the symptoms of neurogenic orthostatic
hypotension. Patients were over the age of 18 in all studies, and any studies attempting to
evaluate the effect of droxidopa on a pediatric population would likely be very difficult and
largely unnecessary, as the conditions that most often cause neurogenic orthostatic hypotension
have a predominance in the older population. Each study analyzed a relatively large group of
patients, with each over 100 participants, and the age ranges were relatively varied for each
study. Every study included in the review did exclude patients who take long-acting
antihypertensive medications, which is reasonable to isolate the adverse effects of the medication
but could pose issues as a relative or total contraindication in the future. Hypertension is a
relatively common issue, especially as age increases, and could be a relatively common
comorbidity in patients that would otherwise benefit from droxidopa treatment.

Longo, Droxidopa & Hypotension, 9

Two of the studies utilized in this review, Biaggioni, et al, and Kaufmann, et al, only
included patients that were identified as responders in their randomization and subsequent study.
In Kaufmann, et al, 263 patients participated in open-label droxidopa optimization, but only 162
responders, or 61.6%, continued to the randomization phase of the trial.8 This certainly poses an
issue when considering the efficacy of droxidopa, as any statistics measuring the drug’s effects
compared to placebo has already not included many patients who the drug would not work for.
This indicates that the numbers of patients who would benefit from its use in clinical practice is
actually lower than the study would indicate. In Biaggioni, et al, a similar trend was seen, as 181
patients entered open-label droxidopa optimization but only 101 entered the randomized and
double-blind portion of the trial, with 24 reported as not meeting responder criteria.6 Of
particular concern here are the 43 patients who did not progress due to adverse effects, including
21 who had a blood pressure elevation. This not only casts doubt on the efficacy of the drug in
clinical practice, but also indicates that this particular study may overstate the safety of
droxidopa by excluding patients with adverse reactions before the randomized trial has begun.
This helps to explain the negative numbers needed to harm seen in this study, and shows that this
study may both overstate droxidopa’s safety and efficacy.
All studies used, once they had reached the randomization stage, were generally well
conducted. All were placebo-controlled and double blind and had relatively few
discontinuations or withdrawals. However, all were conducted utilizing the optimized dose of
droxidopa for each individual patient, defined as between 100-600mg TID. This does exhibit a
potential complication with droxidopa’s use in clinical practice, as this stipulation indicates that
it is not a drug with an easy dosing formula. Optimizing the dosage for each patient may be time
consuming and require a higher amount of office visits than may at first be apparent. In addition,
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the timing of dosing at three times a day may be inconvenient for some patients if continued in
clinical practice. This could decrease the amount of patients who are compliant with treatment
and therefore further decrease the efficacy of droxidopa as a clinical treatment option.
In the study conducted by Hauser, et al, droxidopa did show a significant improvement in
symptoms compared to placebo according to its primary endpoint, OSHA item 1.7 However, this
statistically significant improvement was only seen from baseline to week 1, and a similar
improvement was not exhibited at week 2, 4, and 8, although numerical improvement still was
present compared to placebo.7 This does raise questions on the long-term efficacy of droxidopa
as a treatment for nOH, as it is unclear why this statistical improvement was not continued
throughout the trial. As neurogenic orthostatic hypotension often occurs as a result of chronic
conditions, it is important that any treatment utilized be able to be continued long-term, which
this trial was unable to exhibit.
Finally, it is important to note that droxidopa currently carries a black-box warning issued
by the Food and Drug Administration regarding the risks of supine hypertension with its use.9 It
is therefore recommended that patients must sleep with their head and upper body elevated, in
order to alleviate this potential issue. Although this may be an annoyance to some patients and
could lead to some issues with clinical use, it is important to consider that the only other FDAapproved medication for nOH, midodrine, carries a similar black-box warning.9 As such, there
are not any pharmacologic options that avoid this complication, and given the nature of the
disorder it may be very difficult to develop one that does not carry such a risk.
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Conclusion
The use of droxidopa was exhibited to be effective and safe in each of the studies
analyzed in this review. However, efficacy over placebo was only shown in some of the
endpoints measured to a statistical significance, with others only showing numerical
improvement if any at all. One study also only showed statistical improvement after 1 week, and
was unable to show a continuation of this throughout the study.7 The other two studies also both
selected for responders to droxidopa before randomizing, casting doubt on both their efficacy
and safety data. As such, more studies would need to be conducted before being able to make
any strong recommendations for or against the use of droxidopa in treatment of neurogenic
orthostatic hypotension.
In future studies, it would be important to include patients who pass screening, including
those who may be droxidopa non-responders, in order to fully capture the potential of the drug to
be efficacious in clinical practice. This would also prevent those who experience adverse effects
from being removed before data is collected, so that accurate safety data can be collected.
Studies would also need to be extended long enough to exhibit whether droxidopa can be
expected to improve symptoms in patients long-term, as the data is not strong in this aspect.
Considering the paucity of pharmacologic options for the treatment of neurogenic orthostatic
hypotension, and the efficacy that was exhibited in some of the endpoints measured in the studies
included in this review, droxidopa remains a promising treatment option and would continue to
benefit from further analysis and study.
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